Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 409

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 409
---
 us of their requests by calling or writing us at our principal executive offices at +97143966949 and 3rd Floor Zephyr House, 122 Mary Street, George Town, PO Box 10085, Grand Cayman KY1-1001, Cayman Islands.

### TRANSFER AGENT AND REGISTRAR
The Transfer Agent for the securities of Iris and ParentCo is Continental Stock Transfer & Trust Company.

### SUBMISSION OF STOCKHOLDER PROPOSALS
The Iris Board is aware of no other matter that may be brought before the Special Meeting. Under Delaware law, only business that is specified in the notice of special meeting to stockholders may be transacted at the Special Meeting.

### STOCKHOLDER PROPOSALS
If the Business Combination is consummated and ParentCo holds a 2026 annual meeting of stockholders, it will provide notice of or otherwise publicly disclose the date on which the 2026 annual meeting will be held. If the 2026 annual meeting is held, stockholder proposals will be eligible for consideration by the directors for inclusion in the proxy statement for ParentCo’s 2026 annual general meeting in accordance with Rule 14a-8 under the Exchange Act.

### OTHER STOCKHOLDER COMMUNICATIONS
Stockholders and interested parties may communicate with the Iris Board, any committee chairperson or the non-management directors as a group by writing to the Iris Board or committee chairperson in care of Iris Acquisition Corp, 3rd Floor Zephyr House 122 Mary Street, George Town, P.O. Box 10085, Grand Cayman KY1-1001, Cayman Islands, Attention: Sumit Mehta. Following the Business Combination, such communications should be sent in care of Liminatus Pharma, Inc., 6 Centerpointe Drive, Suite 625, La Palma, CA 90623, Attention: CEO. Each communication will be forwarded, depending on the subject matter, to the ParentCo Board, the appropriate committee chairperson or the non-management directors.

<div align='center'>227</div>

TABLE OF CONTENTS

### WHERE YOU CAN FIND MORE INFORMATION
Iris files reports, proxy statements and other information with the SEC as required by the Exchange Act. You may access information on Iris at the SEC web site containing reports, proxy statements and other information at: http://www.sec.gov.

If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination, you should contact via phone or in writing:

<div